Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

View Full Paper
Ask AI
Bookmark
Share

Authors

FYFan YangXKXiaoyan Ke

Discussion

Loading...

Member takes

Overview

Single-arm study demonstrates high efficacy and manageable adverse events of CD7 CAR T cells in relapsed T-cell lymphoma.

Key Points

  • To evaluate the safety, tolerability, and efficacy of CD7 CAR T cells in patients with relapsed/refractory T-cell lymphoma.
  • Single-arm, open-label, Phase I study
  • Involvement of 40 patients with various T-cell lymphomas
  • Evaluation of CD7 CAR T cells infused at escalating doses
  • Overall response rate of 92.5% with complete remission in 77.5% of patients
  • Cytokine release syndrome occurred in 80% of patients, with manageable adverse events
  • Progression-free survival rates at 3 years of 28.9% for the overall population

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dda2https://doi.org/10.1182/blood-2025-2368
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies2025 · 1 citations
  2. 2CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study2025
  3. 3A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous <scp>CD7</scp> chimeric antigen receptor T‐cell therapy2024 · 13 citations
  4. 4CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma2025 · 1 citations
  5. 5Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation2024 · 4 citations